These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 19698772)

  • 1. Liposomal formulations of glucagon-like peptide-1: improved bioavailability and anti-diabetic effect.
    Hanato J; Kuriyama K; Mizumoto T; Debari K; Hatanaka J; Onoue S; Yamada S
    Int J Pharm; 2009 Dec; 382(1-2):111-6. PubMed ID: 19698772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery.
    Chae SY; Jin CH; Shin HJ; Youn YS; Lee S; Lee KC
    Bioconjug Chem; 2008 Jan; 19(1):334-41. PubMed ID: 18078308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the subchronic antidiabetic effects of DPP IV-resistant GIP and GLP-1 analogues in obese diabetic (ob/ob) mice.
    Irwin N; McClean PL; Flatt PR
    J Pept Sci; 2007 Jun; 13(6):400-5. PubMed ID: 17486662
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biological activity of AC3174, a peptide analog of exendin-4.
    Hargrove DM; Kendall ES; Reynolds JM; Lwin AN; Herich JP; Smith PA; Gedulin BR; Flanagan SD; Jodka CM; Hoyt JA; McCowen KM; Parkes DG; Anderson CM
    Regul Pept; 2007 Jun; 141(1-3):113-9. PubMed ID: 17292977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent.
    Lee KC; Chae SY; Kim TH; Lee S; Lee ES; Youn YS
    Regul Pept; 2009 Jan; 152(1-3):101-7. PubMed ID: 18951927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.
    Green BD; Lavery KS; Irwin N; O'harte FP; Harriott P; Greer B; Bailey CJ; Flatt PR
    J Pharmacol Exp Ther; 2006 Aug; 318(2):914-21. PubMed ID: 16648370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Orally administered glucagon-like peptide-1 affects glucose homeostasis following an oral glucose tolerance test in healthy male subjects.
    Steinert RE; Poller B; Castelli MC; Friedman K; Huber AR; Drewe J; Beglinger C
    Clin Pharmacol Ther; 2009 Dec; 86(6):644-50. PubMed ID: 19727071
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PEGylation improves the hypoglycaemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice.
    Youn YS; Jeon JE; Chae SY; Lee S; Lee KC
    Diabetes Obes Metab; 2008 Apr; 10(4):343-6. PubMed ID: 18034839
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the cellular and biological properties of DPP-IV-resistant N-glucitol analogues of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide.
    Green BD; Gault VA; O'Harte FP; Flatt PR
    Diabetes Obes Metab; 2005 Sep; 7(5):595-604. PubMed ID: 16050953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenoviral vector-mediated glucagon-like peptide 1 gene therapy improves glucose homeostasis in Zucker diabetic fatty rats.
    Lee Y; Kwon MK; Kang ES; Park YM; Choi SH; Ahn CW; Kim KS; Park CW; Cha BS; Kim SW; Sung JK; Lee EJ; Lee HC
    J Gene Med; 2008 Mar; 10(3):260-8. PubMed ID: 18085721
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability.
    Youn YS; Chae SY; Lee S; Jeon JE; Shin HG; Lee KC
    Biochem Pharmacol; 2007 Jan; 73(1):84-93. PubMed ID: 17054919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Physicochemical and pharmacological characterization of alpha-tocopherol-loaded nano-emulsion system.
    Hatanaka J; Chikamori H; Sato H; Uchida S; Debari K; Onoue S; Yamada S
    Int J Pharm; 2010 Aug; 396(1-2):188-93. PubMed ID: 20558261
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and evaluation of oral bioadhesive controlled release formulations of miglitol, intended for prolonged inhibition of intestinal alpha-glucosidases and enhancement of plasma glucagon like peptide-1 levels.
    Deshpande MC; Venkateswarlu V; Babu RK; Trivedi RK
    Int J Pharm; 2009 Oct; 380(1-2):16-24. PubMed ID: 19563873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous glucagon-like peptide-1 improves postprandial glycaemic control over a 3-week period in patients with early type 2 diabetes.
    Todd JF; Edwards CM; Ghatei MA; Mather HM; Bloom SR
    Clin Sci (Lond); 1998 Sep; 95(3):325-9. PubMed ID: 9730852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
    Nauck MA
    Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of surface chemistry of porous silicon microparticles on glucagon-like peptide-1 (GLP-1) loading, release and biological activity.
    Huotari A; Xu W; Mönkäre J; Kovalainen M; Herzig KH; Lehto VP; Järvinen K
    Int J Pharm; 2013 Sep; 454(1):67-73. PubMed ID: 23834832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic, pharmacodynamic, and efficacy profiles of alogliptin, a novel inhibitor of dipeptidyl peptidase-4, in rats, dogs, and monkeys.
    Lee B; Shi L; Kassel DB; Asakawa T; Takeuchi K; Christopher RJ
    Eur J Pharmacol; 2008 Jul; 589(1-3):306-14. PubMed ID: 18538760
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incretin hormone secretion in women with polycystic ovary syndrome: roles of obesity, insulin sensitivity, and treatment with metformin.
    Svendsen PF; Nilas L; Madsbad S; Holst JJ
    Metabolism; 2009 May; 58(5):586-93. PubMed ID: 19375579
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of preparation technique on the properties of liposomes encapsulating ketoprofen-cyclodextrin complexes aimed for transdermal delivery.
    Maestrelli F; González-Rodríguez ML; Rabasco AM; Mura P
    Int J Pharm; 2006 Apr; 312(1-2):53-60. PubMed ID: 16469460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.